Expert Review of Hematology最新文献_第5页

Optimizing long-term joint health in the treatment of hemophilia. 优化血友病治疗中的长期关节健康。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-10-01 Epub Date: 2024-09-08 DOI: 10.1080/17474086.2024.2396617

Roberta Gualtierotti, Andrea Giachi, Chiara Suffritti, Luca Bedogni, Francesco Franco, Francesco Poggi, Sergio Mascetti, Marco Colussi, Dragan Ahmetovic, Valentina Begnozzi, Elena Anna Boccalandro, Luigi Piero Solimeno, Flora Peyvandi

{"title":"Optimizing long-term joint health in the treatment of hemophilia.","authors":"Roberta Gualtierotti, Andrea Giachi, Chiara Suffritti, Luca Bedogni, Francesco Franco, Francesco Poggi, Sergio Mascetti, Marco Colussi, Dragan Ahmetovic, Valentina Begnozzi, Elena Anna Boccalandro, Luigi Piero Solimeno, Flora Peyvandi","doi":"10.1080/17474086.2024.2396617","DOIUrl":"10.1080/17474086.2024.2396617","url":null,"abstract":"Introduction: The improved quality of care and increased drug availability have shifted the goal of treating people with hemophilia from life-threatening bleeding prevention to joint health preservation and quality of life amelioration. Many tools are now available to the clinician in order to optimize the management of hemophilic arthropathy.Areas covered: This paper reviews the pivotal role of ultrasound evaluation in early detection of joint bleeding and differential diagnosis of joint pain, with a focus on the feasibility of a long-term monitoring of joint health through the use of artificial intelligence and telemedicine. The literature search methodology included using keywords to search in PubMed and Google Scholar, and articles used were screened by the coauthors of this review.Expert opinion: Joint ultrasound is a practical point-of-care tool with many advantages, including immediate correlation between imaging and clinical presentation, and dynamic evaluation of multiple joints. The potential of telemedicine care, coupled with a point-of-care detection device assisted by artificial intelligence, holds promises for even earlier diagnosis and treatment of joint bleeding. A multidisciplinary approach including early intervention by physical medicine and rehabilitation (PMR) physicians and physiotherapists is crucial to ensure the best possible quality of life for the patient.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"713-721"},"PeriodicalIF":2.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma. 评估皮罗替尼治疗复发或难治套细胞淋巴瘤的疗效。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-10-01 Epub Date: 2024-08-08 DOI: 10.1080/17474086.2024.2389993

Jacqueline F Wang, Yucai Wang

{"title":"Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma.","authors":"Jacqueline F Wang, Yucai Wang","doi":"10.1080/17474086.2024.2389993","DOIUrl":"10.1080/17474086.2024.2389993","url":null,"abstract":"Introduction: Mantle cell lymphoma (MCL) is an uncommon non-Hodgkin lymphoma that is generally considered incurable. Covalent BTK inhibitors (cBTKi) are the cornerstone of treatment for relapsed or refractory (R/R) MCL, but treatment options are limited and prognosis is poor after cBTKi failure. Pirtobrutinib is a non-covalent BTK inhibitor that has demonstrated excellent efficacy and safety and represents an important new treatment in the evolving treatment landscape of R/R MCL.Areas covered: This review will provide an overview of the therapeutic landscape of R/R MCL, characteristics of pirtobrutinib, and efficacy and safety data of pirtobrutinib in R/R MCL from pivotal clinical trials. PubMed and major hematology conference proceedings were searched to identify relevant studies involving pirtobrutinib.Expert opinion: For patients with R/R MCL that has progressed after treatment with cBTKi, pirtobrutinib is an important and efficacious treatment that confers favorable outcomes. In the post-cBTKi setting, when chimeric antigen receptor (CAR) T-cell therapy is not available or feasible, pirtobrutinib is the preferred treatment for R/R MCL. How to sequence or combine pirtobrutinib with CAR T-cell therapy and other available or emerging therapies requires further investigation. Future studies should also explore the role of pirtobrutinib in earlier lines of therapy for MCL.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"651-659"},"PeriodicalIF":2.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141897188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenges and considerations for antifungal prophylaxis in children with acute myeloid leukemia. 急性髓性白血病患儿抗真菌预防的挑战和注意事项。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-10-01 Epub Date: 2024-08-12 DOI: 10.1080/17474086.2024.2390639

Daniel K Yeoh, Gabrielle M Haeusler, Monica A Slavin, Rishi S Kotecha

{"title":"Challenges and considerations for antifungal prophylaxis in children with acute myeloid leukemia.","authors":"Daniel K Yeoh, Gabrielle M Haeusler, Monica A Slavin, Rishi S Kotecha","doi":"10.1080/17474086.2024.2390639","DOIUrl":"10.1080/17474086.2024.2390639","url":null,"abstract":"Introduction: Children receiving treatment for acute myeloid leukemia (AML) are at high risk of invasive fungal disease (IFD). Evidence from pediatric studies support the efficacy of antifungal prophylaxis in reducing the burden of IFD in children receiving therapy for AML, yet existing antifungal agents have specific limitations and comparative data to inform the optimal prophylactic approach are lacking.Areas covered: This review summarizes the epidemiology of invasive fungal disease (IFD) and current antifungal prophylaxis recommendations for children with acute myeloid leukemia (AML). Challenges with currently available antifungal agents and considerations related to the changing landscape of AML therapy are reviewed. A keyword search was conducted to identify pediatric studies regarding IFD and antifungal prophylaxis in children with AML up to December 2023.Expert opinion: Children undergoing treatment for AML are recommended to receive antifungal prophylaxis to reduce risk of IFD, with tolerability, pharmacokinetics, feasibility of administration, and drug interactions all factors that require consideration in this context. With increased use of novel targeted agents for AML therapy, together with the development of new antifungal agents, data from well-designed clinical studies to optimize prophylactic approaches will be essential to limit the burden of IFD in this vulnerable cohort.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"679-686"},"PeriodicalIF":2.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

DNA damage repair in megakaryopoiesis: molecular and clinical aspects. 巨核细胞生成过程中的 DNA 损伤修复：分子和临床方面。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-10-01 Epub Date: 2024-08-13 DOI: 10.1080/17474086.2024.2391102

Zeinab Eftekhar, Mojtaba Aghaei, Najmaldin Saki

{"title":"DNA damage repair in megakaryopoiesis: molecular and clinical aspects.","authors":"Zeinab Eftekhar, Mojtaba Aghaei, Najmaldin Saki","doi":"10.1080/17474086.2024.2391102","DOIUrl":"10.1080/17474086.2024.2391102","url":null,"abstract":"Introduction: Endogenous DNA damage is a significant factor in the damage of hematopoietic cells. Megakaryopoiesis is one of the pathways of hematopoiesis that ends with the production of platelets and plays the most crucial role in hemostasis. Despite the presence of efficient DNA repair mechanisms, some endogenous lesions can lead to mutagenic alterations, disruption of pathways of hematopoiesis including megakaryopoiesis and potentially result in human diseases.Areas covered: The complex regulation of DNA repair mechanisms plays a central role in maintaining genomic integrity during megakaryopoiesis and influences platelet production efficiency and quality. Moreover, anomalies in DNA repair processes are involved in several diseases associated with megakaryopoiesis, including myeloproliferative disorders and thrombocytopenia.Expert opinion: In the era of personalized medicine, diagnosing diseases related to megakaryopoiesis can only be made with a complete assessment of their molecular aspects to provide physicians with critical molecular data for patient management and to identify the subset of patients who could benefit from targeted therapy.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"705-712"},"PeriodicalIF":2.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia. BTK 抑制剂：慢性淋巴细胞白血病治疗的突破口。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-10-01 Epub Date: 2024-08-21 DOI: 10.1080/17474086.2024.2391097

Alycia Hatashima, Mazyar Shadman

{"title":"BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia.","authors":"Alycia Hatashima, Mazyar Shadman","doi":"10.1080/17474086.2024.2391097","DOIUrl":"10.1080/17474086.2024.2391097","url":null,"abstract":"Introduction: Bruton's tyrosine kinaseinhibitors (BTKis) changed the trajectory of upfront and relapsed/refractory chronic lymphocytic leukemia (CLL) treatment. However, BTKis are plagued by a spectrum of toxicities. Zanubrutinib was developed to circumvent challenges with prolonged tolerability by increasing BTK selectivity and maximizing efficacy through pharmacokinetic/pharmacodynamic optimization. However, with the availability of ibrutinib, acalabrutinib, and zanubrutinib, limited data exists to guide sequencing of BTKi therapy in the relapsed/refractory setting.Areas covered: We review the first head-to-head trial (ALPINE) of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory CLL and compare zanubrutinib's clinical efficacy and toxicities, including in patients with del(17p) and/or TP53 mutations to ibrutinib and acalabrutinib.Expert opinion: Zanubrutinibrepresents one of the new standards of care for relapsed/refractory CLL based on superior progression-free survival and response rates over ibrutinib. Whilezanubrutinib is associated with fewer cardiac toxicities, similar rates of neutropenia and hypertension are noted. Ongoing studies are pushing the envelope, utilizing targeted drug combinations and minimal residual disease markers as well as receptor tyrosine kinase-like orphan receptor 1 inhibitors, chimeric antigen receptor T-cells, and novel BTK degraders. However, zanubrutinibrepresents a strong contender in the arsenal of treatment options for relapsed/refractory CLL.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"687-703"},"PeriodicalIF":2.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142008570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Applications of artificial intelligence to myeloproliferative neoplasms: a narrative review. 人工智能在骨髓增生性肿瘤中的应用：综述。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-10-01 Epub Date: 2024-08-13 DOI: 10.1080/17474086.2024.2389997

Andrew Srisuwananukorn, Jordan E Krull, Qin Ma, Ping Zhang, Alexander T Pearson, Ronald Hoffman

{"title":"Applications of artificial intelligence to myeloproliferative neoplasms: a narrative review.","authors":"Andrew Srisuwananukorn, Jordan E Krull, Qin Ma, Ping Zhang, Alexander T Pearson, Ronald Hoffman","doi":"10.1080/17474086.2024.2389997","DOIUrl":"10.1080/17474086.2024.2389997","url":null,"abstract":"Introduction: Artificial intelligence (AI) is a rapidly growing field of computational research with the potential to extract nuanced biomarkers for the prediction of outcomes of interest. AI implementations for the prediction for clinical outcomes for myeloproliferative neoplasms (MPNs) are currently under investigation.Areas covered: In this narrative review, we discuss AI investigations for the improvement of MPN clinical care utilizing either clinically available data or experimental laboratory findings. Abstracts and manuscripts were identified upon querying PubMed and the American Society of Hematology conference between 2000 and 2023. Overall, multidisciplinary researchers have developed AI methods in MPNs attempting to improve diagnostic accuracy, risk prediction, therapy selection, or pre-clinical investigations to identify candidate molecules as novel therapeutic agents.Expert opinion: It is our expert opinion that AI methods in MPN care and hematology will continue to grow with increasing clinical utility. We believe that AI models will assist healthcare workers as clinical decision support tools if appropriately developed with AI-specific regulatory guidelines. Though the reported findings in this review are early investigations for AI in MPNs, the collective work developed by the research community provides a promising framework for improving decision-making in the future of MPN clinical care.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"669-677"},"PeriodicalIF":2.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations. venetoclax治疗后急性髓性白血病的复发和耐药性：改进二线疗法和联合疗法。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-10-01 Epub Date: 2024-09-13 DOI: 10.1080/17474086.2024.2402283

Rabia Shahswar, Arnold Ganser

{"title":"Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations.","authors":"Rabia Shahswar, Arnold Ganser","doi":"10.1080/17474086.2024.2402283","DOIUrl":"10.1080/17474086.2024.2402283","url":null,"abstract":"Introduction: The combined use of the BCL-2 inhibitor venetoclax with azacitidine now is the standard of care for patients with acute myeloid leukemia (AML) unfit for intensive chemotherapy with outcomes exceeding those achieved with hypomethylating agents alone. Venetoclax in combination with intensive chemotherapy is also increasingly used both as frontline as well as salvage therapy. However, resistance to and relapse after venetoclax-based therapies are of major concern and outcomes after treatment failure remain poor.Areas covered: A comprehensive search was performed using PubMed database (up to April 2024). Studies evaluating venetoclax-based combination treatments in AML and studies assessing markers of response and resistance to venetoclax were investigated. We summarize the status of venetoclax-based therapies in the frontline and relapsed/refractory setting with focus on the main mechanisms of resistance to BCL-2 inhibition. Further, strategies to overcome resistance including combinatorial regimens of hypomethylating agent (HMA) + venetoclax + inhibitors targeting actionable mutations like IDH1/2 or FLT3-ITD and the introduction of novel agents like menin-inhibitors are addressed.Expert opinion: Although venetoclax is reshaping the treatment of unfit and fit AML patients, prognosis of patients after HMA/VEN failure remains dismal, and strategies to abrogate primary and secondary resistance are an unmet clinical need.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"723-739"},"PeriodicalIF":2.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies. Emicizumab 和接受替代疗法的 a 型血友病患者尚未满足的需求。

IF 2.8 4区医学

Expert Review of Hematology Pub Date : 2024-09-09 DOI: 10.1080/17474086.2024.2402304

Johnny Mahlangu

{"title":"Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies.","authors":"Johnny Mahlangu","doi":"10.1080/17474086.2024.2402304","DOIUrl":"https://doi.org/10.1080/17474086.2024.2402304","url":null,"abstract":"INTRODUCTIONHemophilia A is managed with coagulation clotting factor VIII (FVIII) therapy that poses significant challenges, such as a high treatment burden, immunogenicity, inconsistent hemostatic cover, poor treatment outcomes, and musculoskeletal progression despite adequate prophylactic treatment. Various non-factor therapies, such as several natural anticoagulant inhibitors and factor FVIII mimetics, have been developed to address these unmet needs. However, the role of emicizumab in addressing these unmet needs remains underexplored.AREAS COVEREDThis review delves into the evolution of hemophilia A replacement clotting therapy from plasma-derived products to recombinant products and, more recently, nonfactor therapies. It underscores the unmet needs of replacement therapy and explores the nonfactor therapies developed to address them. The review then comprehensively summarizes the clinical trial and real-world experience data, demonstrating how emicizumab tackles these unsatisfied demands.EXPERT OPINIONReplacement clotting factor therapies as the standard of care has exposed several needs that have yet to be addressed. However, data from numerous emicizumab clinical trials and real-world experience offer a promising outlook, suggesting that it may effectively address many unmet needs. As hemophilia treatment goals continue to evolve, the role of currently developed nonfactor therapies in hemophilia management is yet to be fully defined.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":"65 1","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142204687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management. 免疫性血小板减少症与妊娠：诊断和管理的挑战与机遇。

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-09-01 Epub Date: 2024-08-06 DOI: 10.1080/17474086.2024.2385481

Marina Beltrami-Moreira, Amy Sharma, James B Bussel

{"title":"Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management.","authors":"Marina Beltrami-Moreira, Amy Sharma, James B Bussel","doi":"10.1080/17474086.2024.2385481","DOIUrl":"10.1080/17474086.2024.2385481","url":null,"abstract":"Introduction: Immune thrombocytopenia (ITP) affecting pregnancy is a diagnostic and often a therapeutic challenge.Areas covered: We review the current diagnostic criteria for ITP in pregnancy and the potential utility of laboratory tests. We discuss the impact of ITP on pregnancy outcomes and the effects of pregnancy on patients living with chronic ITP. We describe the criteria for intervention, the evidence supporting first-line treatment approaches and the therapeutic decisions and challenges in cases refractory to steroids and IVIG. We review the evidence supporting the potential use of thrombopoietin receptor agonists for refractory thrombocytopenia. Finally, we describe the diagnostic, prognostic, and treatment approaches to neonatal ITP and considerations regarding breastfeeding. We searched the terms 'immune thrombocytopenia' and 'pregnancy' on PubMed to identify the relevant literature published before 31 December 2023, including within cited references.Expert opinion: Decreased platelet production may play a role in pregnancy-related ITP exacerbation. Putative mechanisms include placental hormones, such as inhibin. Although IVIG and prednisone usually suffice to achieve hemostasis for delivery, second-line agents are sometimes required to allow for neuraxial anesthesia. There is growing evidence supporting the use of romiplostim during pregnancy; however, its risk of venous thromboembolism warrants further evaluation.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"595-607"},"PeriodicalIF":2.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141893299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What is the future of digital tools to help manage pain in sickle cell disease patients? 帮助镰状细胞病患者控制疼痛的数字工具的前景如何？

IF 2.3 4区医学

Expert Review of Hematology Pub Date : 2024-09-01 Epub Date: 2024-08-06 DOI: 10.1080/17474086.2024.2388188

Carlton Dampier

引用次数: 0